The purpose of this study is to investigate the role of circulating tumor cells (CTCs) in patients with prostate cancer. Patients who have prostate cancer can develop metastases where the cancer spreads outside the prostate into other organs. It is believed that this occurs from tumor cells that circulate in the bloodstream.

This study is open to individuals who contracted an infection with adenovirus after receiving an allogeneic hematopoietic cell transplant (HCT). Adenoviruses (AdV) are a group of common viruses that infect the lining of the eyes, airways, intestines, urinary tract, and nervous system, and can cause mild to severe illness.

The purpose of this study is to test whether a new investigational drug called Pegcetacoplan can reduce some of the symptoms experienced by patients with cold agglutinin disease (CAD), also sometimes known as cold antibody hemolytic anemia. Researchers also want to test the tolerability of the drug to make sure it is safe for people with CAD to use.

Investigational means that the study drug is currently being tested and it has not yet been approved by the US Food and Drug Administration (FDA). 

This is a clinical trial for adults diagnosed with relapsed (has come back) or refractory (has not responded to treatment) acute myeloid leukemia (AML).

The goal of Phase 1 of this study is to test the safety and tolerability of up to 5 different doses of the investigational medication UCART123 and to find the best dose of UCART123 that can be given to patients with AML that is relapsed or refractory.   

This clinical trial is for men and women with B-cell Non-Hodgkin Lymphoma (NHL).
   
The purpose of this study is to study is to assess the safety and effectiveness of odronextamab in destroying participant's cancer cells. Odronextamab is an investigational drug, which means it has not yet been approved by the U.S. Food and Drug Administration (FDA).
   

This clinical trial is for participants with relapsed/refractory follicular lymphoma.

The purpose of this study is to understand more about whether the investigational drug, tazemetostat, in combination with lenalidomide and rituximab will be a useful treatment for people with relapsed/refractory follicular lymphoma. An investigational drug means that it has not yet been approved by the United States Food and Drug Administration (FDA).

This study is for men and women who have undergone surgery for a neurological condition, including brain tumors, vascular disorders such as aneurysms or arteriovenous malformations, or elective surgery for epilepsy or Chiari malformation.
   

This clinical trial is for adult participants who have breast cancer that is advanced or that has spread to other parts of the body.
   
The purpose of this study is to evaluate the safety and effectiveness of a new drug called gedatolisib when combined with other cancer drugs, compared to the standard of care. The standard of care is a drug or drug combination that is usually given to patients with breast cancer. Gedatolisib, which is intended to slow or stop the growth of cancer, is not yet approved by the United States Food and Drug Administration (FDA).

This study is for men and women who have been diagnosed with cancer of unknown primary (CUP) origin.
   
The purpose of this study is to understand specific changes in the genes of patients with cancers of unknown primary, a relatively common disease that accounts for about 3–9% of all cancer diagnoses. In the USA alone, this occurs in more than 80,000 patients every year.

This study is for men and women recently diagnosed with and/or under treatment for cancer at Weill Cornell Medicine/NewYork-Presbyterian Hospital.